<DOC>
	<DOCNO>NCT01234298</DOCNO>
	<brief_summary>To assess safety efficacy SPD489 low-dose high-dose treatment group placebo give adjunctive therapy antipsychotic medication clinically stable adult persistent predominant negative symptom schizophrenia .</brief_summary>
	<brief_title>SPD489 Adjunctive Treatment Adults With Negative Symptoms Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Subject diagnosis schizophrenia least 2 year Subject persistent predominant negative symptom Subject 2 persistent predominant negative symptom ( affective flattening , alogia , avolition apathy , anhedoniaasociality ) determine present least 6 month Subject maintain antipsychotic monotherapy polytherapy 2 antipsychotic medication Subject clinically stable nonacute phase illness Subject clinically notable positive symptom Subject consider treatment refractory Subject current history substance abuse/dependance Subject consider suicide risk risk harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>